Inferra AIResearch Tools

Inferra AI / Company / PTCT

Ptc Therapeutics, Inc.

PTCT · Health Care

Last earnings Oct 29, 2026

Key results

Revenuequarter

$19.6M

revenue of $19.6M and 521 start forms in the US as of September 30 Robust Q3 performance with total

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

revenue of $211.0 million Global launch of Sephience initiated in US and Europe o Third quarter 2025

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Total revenuequarter

$211.0 million

Total revenue was $211.0 million for the third quarter of 2025, compared to $196.8 million for the third quarter of 2024.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Total revenue includes net product revenue across the commercial portfolio of $131.0 million for the third quarter of 2025, compared to $135.4 million for the third quarter of 2024.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Total revenue also includes royalty, collaboration and license revenue of $80.1 million for the third quarter of 2025, compared to $61.4 million for the third quarter of 2024.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Sephience net product revenue was $19.6 million for the third quarter of 2025.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Translarna net product revenue was $50.7 million for the third quarter of 2025, compared to $72.3 million for the third quarter of 2024.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Emflaza net product revenue was $35.2 million for the third quarter of 2025, compared to $51.9 million for the third quarter of 2024.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

AI analysis

Q3 2025 · reported Nov 4, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 2025
$19.6M
-90.0% -$177M vs year ago computed from stated figures
EX-99 · Nov 4, 2025
Total revenue · Q3 2025
$211.0M
+17.9% vs prior quarter computed from stated figures
+7.2% vs year ago computed from stated figures
EX-99 · Nov 4, 2025

The quarter in charts

Revenue — quarterly

As stated

083.3167250$196.8MSame quarter last year$19.6MQ3 2025

EX-99 · Nov 4, 2025 Statement values as stated in the release.

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Nov 4, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue$19.6M$179M$196.8 million
Total revenue$211.0 million$179M$196.8 million

EX-99 · Nov 4, 2025

Guidance · company-stated

Direction: Initiated

Revenue$19.6M

“htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Initiated US and EU launch of Sephience (sepiapterin) Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 Robust Q3 performance with total revenue of $211M Full-year 2025 revenue guidance narrowed to $750 - $800M WARREN, N.”

Midpoint vs latest-quarter revenue0.0%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Ptc Therapeutics, Inc. Q3 2025 — revenue of $19.6M and 521 start forms in the US as of September 30 Robust Q3 performance with total

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Initiated

Revenue: “htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Initiated US and EU launch of Sephience (sepiapterin) Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 Robust Q3 performance with total revenue of $211M Full-year 2025 revenue guidance narrowed to $750 - $800M WARREN, N.”

Revenue — Initiated (“Initiated”)
“htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Initiated US and EU launch of Sephience (sepiapterin) Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 Robust Q3 performance with total revenue of $211M Full-year 2025 revenue guidance narrowed to $750 - $800M WARREN, N.”

Classified from the release's primary full-year outlook statement.

Strategy & priorities

The company s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

What changed vs prior quarter

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Total revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Ptc Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Documents

Earnings deck slides

0 decks with slide view

Ptc Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Ptc Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Ptc Therapeutics, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

34 documents

Earnings releases

11 documents

Presentations

3 documents

Transcripts

0 documents

No transcripts for Ptc Therapeutics, Inc. are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Ptc Therapeutics, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.